Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Credit agrmnt [a]
Appointed director
Kadmon Holdings, Inc. (KDMN) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/09/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accele...
Docs: "Amended and Restated Certificate of Incorporation of the Company",
"Amended and Restated Bylaws of the Company",
"First Supplemental Indenture, by and between Kadmon Holdings, Inc. and U.S. Bank National Association, as Trustee",
"Paris – November 9, 2021 - Sanofi announced today the completion of its acquisition of Kadmon Holdings, Inc. The acquisition further strengthens growth and expansion for the"
11/05/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
11/04/2021 8-K Quarterly results
Docs: "REZUROCK™ · On August 19, 2021 REZUROCK became commercially available for shipment to prescribed patients in the United States through a network of rare hematology/oncology specialty pharmacies and distributors o Execution of commercial launch remain underway, with a focus on generating awareness of REZUROCK's differentiated clinical value and facilitating market access o Experienced field team call on all target accounts, including engagement with 100% of the top 80 transplant centers, where ~90% of chronic graft-versus-host disease patients in the U.S. are treated o Strong sales performance and demand during initial launch period; $12.2 million net sales achieved in 3Q 2021 o The Company plans to present data on belumosudil at the 63rd American Society of Hematology Annual Me..."
10/27/2021 8-K Other Events  Interactive Data
10/21/2021 8-K Other Events  Interactive Data
09/08/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
07/19/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "U.S. FDA Grants Full Approval of REZUROCK™ for the Treatment of Patients with Chronic Graft-Versus-Host Disease"
05/12/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/01/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
02/10/2021 8-K Quarterly results
01/12/2021 8-K Quarterly results
12/07/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Kadmon Announces 12-Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting",
"Exhibit 99.2"
11/30/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Kadmon Announces FDA Acceptance of NDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease"
11/05/2020 8-K Quarterly results
Docs: "About Belumosudil Belumosudil is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 , a signaling pathway that modulates inflammatory response and pro-fibrotic processes. The Company has submitted an NDA for belumosudil for the treatment of patients with cGVHD and the NDA is being reviewed under the FDA’s RTOR pilot program. The FDA has granted Breakthrough Therapy Designation to belumosudil for the treatment of patients with cGVHD after failure of two or more lines of systemic therapy. The FDA has also granted Orphan Drug Designation to belumosudil for the treatment of cGVHD. In addition, belumosudil is in Phase 2 clinical development in patients with diffuse cutaneous systemic sclerosis . The FDA has granted Orphan Drug Designation to belumosudil for the treatment of syste..."
10/13/2020 8-K Quarterly results
09/30/2020 8-K Quarterly results
08/13/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
06/23/2020 8-K Quarterly results
05/21/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil in Chronic Graft-Versus-Host Disease ORRs of 73% and 74% with Belumosduil 200 mg QD and 200 mg BID, Respectively",
"Presentation slides, of Kadmon Holdings, Inc"
05/14/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/10/2020 8-K Quarterly results
03/05/2020 8-K Quarterly results
02/24/2020 8-K Quarterly results
11/19/2019 8-K Quarterly results
11/14/2019 8-K Quarterly results
11/12/2019 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Kadmon Provides Business Update and Reports Third Quarter 2019 Financial Results NEW YORK, November 7, 2019 – Kadmon Holdings, Inc. today provided a business update and reported financial and operational results for the third quarter of 2019."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy